Key result
Real-world lixisenatide linked to ~0.8-point lower HbA1c at 26 weeks.
Observational
Yes
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Lixisenatide has been studied extensively in randomized clinical trials; however, data on its use in the real-life practice are scarce. METHODS: This study was a prospective, 26-week, multicenter, observational study conducted in Austrian diabetes centers and office-based practices to evaluate efficacy and safety of lixisenatide under real-life conditions in patients with type 2 diabetes. The HbA1c declined from 8.7% (72 mmol/mol) to 7.9% (63 mmol/mol) and at study end 24.8% of the patients reached an HbA1c level below 7%. Fasting and postprandial glucose after lixisenatide administration were reduced by 27 ± 58 mg/dl and 45 ± 67 mg/dl, respectively. At study end body weight (- 4.5 ± 5.4 kg), triglycerides (- 10.8 ± 105 mg/dl), systolic blood pressure (- 4.8 ± 17.1 mmHg), and LDL cholesterol (- 3.7 ± 25 mg/dl) were reduced. The most commonly reported adverse events were gastrointestinal disorders (18.8%). Forty-three patients (30%) discontinued prematurely, mostly caused by lack of efficacy, occurrence of gastrointestinal disorders, and missing reimbursement. The average dose of insulin decreased slightly by 1.5 units (from 29.4 to 27.9). CONCLUSION: Lixisenatide demonstrated a similar efficacy and safety profile under real-life conditions as previously shown in randomized clinical trials. FUNDING: sanofi-aventis GmbH Austria.
No takes yet. Share an insight, caveat, or question.
Brath et al. (2019) conducted an observational in Type 2 diabetes. Lixisenatide was evaluated on HbA1c level and achievement of HbA1c <7%. Lixisenatide under real-life conditions reduced HbA1c from 8.7% to 7.9% at 26 weeks, with 24.8% of patients achieving HbA1c <7% and a mean body weight reduction of 4.5 kg.
Synapse has enriched 10 related papers. Consider them for comparative context: